Chinese Academy of Sciences

Shanghai Haihe Pharmaceutical Co., Ltd.

Shanghai Lead Discovery Pharmaceuticals Limited Company

Bing Xiong

Jingkang Shen

Meiyu Geng

Xia Peng

Tao Meng

Yinchun Ji

Danqi Chen

Jing Lan Chen

Xin Wang

Jian Ding

Jia Tao Li

Qi Rong Wang

Hong Tao Liu

Hualiang Jiang

Fei Ye

Kaixian Chen

Tao Sun

Jing Ai

Jianping Zuo

Jianhua Shen

Zehong Miao

Lanping Ma

Xiaomin Luo

Xu Shen

Yi Zang

Shanshan Song

Lili Chen

Haibin Luo

Qian Tan

Jianping Hu

Donglu Bai

Yiming Yang

Xuchang He

Ying Dong

Jing Al

Yuchi Ma

Yuelei Chen

Yingqing Wang

Chunshan Gui

Yifu Yang

Xianhan Zhuang

Qi Wang

The present disclosure relates to a fused ring pyrimidine amino compound and a preparation method, a pharmaceutical composition, and a use thereof. Specifically disclosed in the present disclosure are the compound shown in formula I, a pharmaceutically acceptable salt thereof, a tautomer thereof, a stereoisomer thereof, a metabolite thereof, a metabolic precursor thereof, or a prodrug thereof. The fused ring pyrimidine amino compound of the present application has good inhibitory activity against DDRs, particularly DDR2, and has a good therapeutic effect on tumors and fibrotic diseases, especially pulmonary inflammation and pulmonary fibrosis. Also disclosed in the present disclosure are a preparation method for the compound shown in formula I, and a use thereof. 

Fused ring pyrimidine amino compound and preparation method, pharmaceutical composition, and use thereof

The present invention relates to dihydroquinoxaline bromodomain recognition protein inhibitor, preparation method and use thereof. The inhibitor of the present invention is compound represented by general formula (I), or stereoisomer, pharmaceutically acceptable salt, prodrug, solvate, hydrate and crystal form thereof. The definition of each substituent is as described in the description and claims. The compound represented by general formula (I) of the present invention may inhibit bromodomain recognition protein and may be used for preparing medicament which regulates the apparent state of cells and treats series of diseases and symptoms which are mediated by the bromodomain recognition protein. 

Dihydroquinoxaline bromodomain recognition protein inhibitor, preparation method and use thereof

This invention provides a class of five-member-heterocycle fused pyridine compounds as shown below in Formula (X), pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof, a method of producing the same, pharmaceutical compositions containing the compound, and use of the compounds in preparing medicament for preventing and/or treating diseases and tumors associated with abnormal protein tyrosine kinase. 

Five-member-heterocycle fused pyridine compounds, method of producing the same, and use thereof

The present invention discloses 3D-structure of SARS-CoV Viral 3CL Protease obtained through molecular simulation. The 3D-structure is used as a drug target for screening the existing medical database CMC (Comprehensive Medicinal Chemistry, MDL Information System, Inc.), and a group of compounds which have the activity of inhibiting SARS-CoV virus 3CL Protease are found. Cinanserin was tested at molecular and viral levels, and it was found to be able to inhibit the SARS-CoV viral 3CL protease and SARS-CoV viruses. Cinanserin analogs were synthesized and tested at molecular and viral levels, they were found to be able to inhibit the SARS-CoV virus 3CL Protease and SARS-CoV viruses, and may be used for treating and/or preventing SARS-CoV virus infection.

3D-structure model of SARS coronavirus 3CL protease and anti-SARS drugs

Growing community of inventors

Shanghai, China

Bing Xiong